The combination of anti-PD-1 and FMT induced a response to immunotherapy in PD-1-resistant melanoma patients (6 of 15 patients) by increasing CD8+ T cells and decreasing IL-8-expressing myeloid cells. The gene discussed is CD8A; the disease is melanoma.